🇦🇹 Austria Country × Condition
metastatic breast cancer Clinical Trials in Austria
Active clinical trials for metastatic breast cancer with research sites in Austria. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 3 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇦🇹 Austria
Active Trials in Austria (2)
NCT07085767 Phase 3
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Enrollment
1,000 pts
Country
🇦🇹 Austria
Olema Pharmaceuticals, Inc.
View Trial → NCT05945732
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
Enrollment
2,295 pts
Country
🇦🇹 Austria
Daiichi Sankyo Europe, GmbH, a Daii...
View Trial → Frequently Asked Questions
How many metastatic breast cancer clinical trials are active in Austria?
There are currently 2 active clinical trials for metastatic breast cancer with sites in Austria, of which 2 are actively recruiting patients.
How can I join a metastatic breast cancer clinical trial in Austria?
To join a metastatic breast cancer clinical trial in Austria, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Austria directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are metastatic breast cancer trials in Austria?
Active metastatic breast cancer trials in Austria span Phase 3. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology